5 recruiting, 4 completed, 2 active not recruiting, 1 suspended. 8 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 4, Active not recruiting 2, Suspended 1, Terminated 1 |
| Phase 2 | 5 | Recruiting 4, Terminated 1 |
Follow Receptors, Chimeric Antigen: new trials by email Literature Review of Receptors, Chimeric Antigen trials Research Report on Receptors, Chimeric Antigen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection Chimeric Antigen Receptor - Lymphoma, Non-Hodgkin | Recruiting | Ruijin Hospital | 1000 | 2024-05-15 | 2024-08-19 | |
| Pembro Plus CAR T-cell Therapy in R/R in PMBCL Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion - Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma | Phase 2 | Recruiting | Jennifer Crombie, MD | 35 | 2023-11-15 | 2026-03-05 |
| CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study Chimeric Antigen Receptor - Lymphoma | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 48 | 2023-11-02 | 2023-10-30 | |
| Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma AutoSCT OR CAR T-cell Therapy, GDP, Epcoritamab - Large Cell Lymphoma, Diffuse, Relapsed Cancer | Phase 2 | Recruiting | Dipenkumar Modi | 35 | 2023-10-31 | 2026-07-10 |
| Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 27 | 2023-05-19 | 2026-09-16 |
| Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma Bridging radiation therapy, Liso-cel, Post-infusion radiation - DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | University of Nebraska | 33 | 2023-03-21 | 2026-10-08 |
| Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR), Treg CD34+HSPC (Orca-T) - Lymphoid Leukemia | Phase 1 | Active not recruiting | Melody Smith | 22 | 2022-08-18 | 2026-09-28 |
| Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) - B-Cell Lymphoma, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | John Lister | 30 | 2022-04-19 | 2025-01-13 |
| Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors chimeric antigen receptor (CAR) T cell therapy - HER-2 Gene Amplification, HER2-positive Gastric Cancer | Phase 1 | Suspended | Bellicum Pharmaceuticals | 220 | 2020-12-07 | 2023-04-20 |
| T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma Cyclophosphamide, Fludarabine, Rimiducid - Myeloma-Multiple, Myeloma, Plasma-Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 13 | 2019-06-13 | 2021-09-09 |
| T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma Cyclophosphamide, Fludarabine, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells - Myeloma-Multiple, Myeloma, Plasma-Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2018-09-14 | 2026-06-16 |
| T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine - Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2017-03-17 | 2023-01-18 |
| Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma Cyclophosphamide, Fludarabine, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells - Myeloma, Plasma-Cell, Myeloma-Multiple | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2014-08-12 | 2019-10-08 |
| Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin, Cyclophosphamide, Fludarabine - Metastatic Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2008-11-01 | 2015-10-28 |
Lymphoma, Large B-Cell, Diffuse (4) · Multiple Myeloma (3) · Lymphoma, Follicular (2) · Lymphoma, Non-Hodgkin (2) · Neoplasms (2) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Enteropathy-Associated T-Cell Lymphoma (1) · Immunoblastic Lymphadenopathy (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Lymphoid (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1)
National Cancer Institute (NCI) (5) · Bellicum Pharmaceuticals (1) · Dipenkumar Modi (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jennifer Crombie, MD (1) · John Lister (1) · Melody Smith (1) · Ruijin Hospital (1) · University of Nebraska (1)
United States (12) · China (1)
James N Kochenderfer, M.D. (4) · Christopher R D'Angelo, MD (1) · Dipenkumar Modi, MD (1) · Jennifer Crombie, MD (1) · John Lister, MD (1) · Lori Muffly, MD (1) · Michael Jain, MD, PhD (1) · Steven A Rosenberg, M.D. (1)
PMID 26370838, PMID 27412889, PMID 29812997, PMID 37939262, PMID 41671463, PMID 41702648
P01CA049605 (1)